Background/Aims: This study was designed to elucidate the clinical significance of serum uric acid (SUA) and the relationship between hyperuricemia and renal prognosis in IgA nepropathy. Methods: The correlation between SUA and other clinical parameters were examined in 748 IgA nephropathy patients (432 males and 316 females). Among these patients, 226 (144 males and 82 females) who were followed for more than 5 years were examined for the relationship between hyperuricemia and renal prognosis. Results: In IgA nephropathy, SUA correlated negatively with creatinine clearance (Ccr), and positively with urinary protein and tubulointerstitial damage. SUA was higher in patients with hypertension or diffuse proliferative glomerulonephritis. Hyperuricemia was a risk factor for renal prognosis, both in terms of serum creatinine (p = 0.0025) and Ccr (p = 0.0057). In 56 patients with normal Ccr at renal biopsy, the change of Ccr after more than 8 years was –22.3 ± 20.8% in 13 patients with hyperuricemia, compared with +2.6 ± 39.4% in 43 patients without hyperuricemia (p = 0.0238). Hyperuricemia was related independently to deterioration of Ccr (p = 0.0461). Conclusion: Hyperuricemia in IgA nephropathy is derived from both glomerular and tubulointerstitial damage, and correlated with hypertension. Hyperuricemia is a risk factor for renal prognosis in IgA nephropathy.

1.
Levy MB, Berger J: Worldwide perspective of IgA nephropathy. Am J Kidney Dis 1988;12:340–347.
2.
Schena FP: A retrospective analysis of the natural history of primary IgA nephropathy world wide. Am J Med 1990;89:209–215.
3.
Koyama A, Igarashi M, Kobayashi M, members and co-workers of the Research Group on Progressive Renal Diseases: Natural history and risk factors for immunoglobulin A nephropathy in Japan. Am J Kidney Dis 1997;29:526–532.
4.
Ward HJ: Uric acid as an independent risk factor in the treatment of hypertension. Lancet 1998;352:670–671.
5.
Alderman MH, Cohen H, Madhavan S, Kivlighn S: Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension 1999;34:144–150.
6.
Culleton B, Larson MG, Kannel WB, Levy D: Serum uric acid and risk for cardiovascular disease and death: The Framingham Heart Study. Ann Intern Med 1999;131:7–13.
7.
Nakajima H, Takemura K, Hanafusa T, Matsuzawa Y: Consensus conference on the management of hyperuricemia in Japan. Purine Pyrimidine Metab 1996;20:154–158.
8.
Danovich GM, Weinberger J, Berlyne GM: Uric acid in advanced renal failure. Clin Sci 1972;43:331–341.
9.
Sorensen LB, Levinson DJ: Origin and extrarenal elimination of uric acid in man. Nephron 1975;14:7–20.
10.
Hatch M, Vaziri ND: Enhanced enteric excretion of urate in rats with chronic renal failure rat. Clin Sci 1994;86:511–516.
11.
Vaziri ND, Freel RW, Hatch M: Effect of chronic experimental renal insufficiency on urate metabolism. J Am Soc Nephrol 1995;6:1313–1317.
12.
Johnson RJ, Schreiner GF: Hypothesis: The role of acquired tubulointerstitial disease in the pathogenesis of salt-dependent hypertension. Kidney Int 1997;52:1169–1179.
13.
Manitius J, Biedunkiewicz B, Kustosz J, Butkowski B: The relationship between insulin, glucose and serum uric acid and their contribution to the progression of renal damage in patients with primary glomerulonephritis. J Int Med Res 1996;24:449–453.
14.
Leyva F, Anker SD, Godsland F, Teixeria M, Hellewell PG, Kox WJ: Uric acid in heart failure: A marker of chronic inflammation. Eur Heart J 1998;19:1814–1822.
15.
Ranieri E, Gesualdo L, Petrarulo F, Schena EP: Urinary IL-6/EGF ratio: A useful prognostic marker for the progression of renal damage in IgA nephropathy. Kidney Int 1996;50:1990–2001.
16.
Hooper DC, Spitsin S, Kean RB, Champion JM, Dickson GM, Chaudhry I, Koprowski H: Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci USA 1998;95:657–680.
17.
Saura C, Dean RT, May J, Stocker R: Human atherosclerosis plaque contains both oxidized lipids and relatively large amounts of alpha-tocopherol and ascorbate. Arterioscler Thromb Vasc Biol 1995;15:1616–1624.
18.
Syrjänen J, Mustonen J, Pasternack A: Hypertriglyceridaemia and hyperuricaemia are risk factors of IgA nephropathy. Nephrol Dial Transplant 2000;15:34–42.
19.
Tsunoda K, Abe K, Hagino T, Omata K, Misawa S, Imai Y, Yosinaga K: Hypotensive treatment of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension. Am J Hypertens 1993;6:28–32.
20.
Cattran DC, Greenwood C, Ritchie S: Long-term benefit of angiotensin-converting enzyme inhibitor therapy in patients with severe IgA nephropathy: A comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy. Am J Kidney Dis 1994;23:247–254.
21.
Okada H, Suzuki H, Kanno Y, Ikenaga H, Saruta T: Renal responses to angiotensin receptor antagonist and angiotensin-converting enzyme inhibitor in partially nephrectomized spontaneously hypertensive rats. J Cardiovasc Pharmacol 1995;26:564–569.
22.
de Zeeluw D, Gansevoort R: Losartan in patients with renal insufficiency. Can J Cardiol 1995;11:41F–44F.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.